Hanall Biopharma (009420) — Cash Flow Quality Index
Hanall Biopharma (009420) has a Cash Flow Quality Index of 24.56x as of September 2025. Operating cash flow of ₩7.34 Billion exceeds net income of ₩298.96 Million, indicating high earnings quality where cash backs reported profits. Explore Hanall Biopharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hanall Biopharma Cash Flow Quality Index (2016–2023)
Historical Cash Flow Quality Index for Hanall Biopharma across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 009420 operating cash flow.
Annual Cash Flow Quality Index for Hanall Biopharma (2016–2023)
Year-by-year earnings quality comparison for Hanall Biopharma.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 8.45x | ₩29.64 Billion | ₩3.51 Billion | ▼ -33.3% |
| 2022 | 12.68x | ₩25.20 Billion | ₩1.99 Billion | ▲ +14992.1% |
| 2021 | 0.08x | ₩839.87 Million | ₩10.00 Billion | ▲ +97.7% |
| 2020 | 0.04x | ₩929.29 Million | ₩21.87 Billion | ▼ -96.0% |
| 2019 | 1.07x | ₩20.49 Billion | ₩19.17 Billion | ▲ +217.8% |
| 2018 | -0.91x | ₩-2.99 Billion | ₩3.30 Billion | ▼ -112.5% |
| 2017 | 7.25x | ₩42.14 Billion | ₩5.81 Billion | ▲ +271.8% |
| 2016 | 1.95x | ₩3.95 Billion | ₩2.03 Billion | — |